FDA Approves Mitomycin Intravesical Solution for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 31, 2025 663 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ENVISION study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR AI and remote monitoring are shaping a new patient journey in... August 26, 2025 Shorter Course of Radiation Is Effective, Safe for Some with Early-Stage... November 30, 2022 Bride Diagnosed with Stage IV Triple-Negative Breast Cancer 6 Months Before... June 17, 2020 Longest Follow-Up of CAR T-Cell Therapy in Mantle Cell Lymphoma Points... June 14, 2022 Load more HOT NEWS EMA Recommends Extension of Indications for Dostarlimab Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases Tennis Legend Chris Evert Says She’s Been Diagnosed with Ovarian Cancer Trial Results Highlight Changing Lung Cancer Treatment Landscape
